Dr Andy Massey is currently Head of Oncology and Cell Biology having joined Vernalis in 2002 after completing his PhD and post-doc with Cancer Research UK. His group focuses on the development and application of cellular assays to support and progress compounds from target validation to hit ID, and then through lead optimisation and into early pre-clinical development. He also has responsibility for managing the DEL screening activities at the Cambridge site. Additionally, he has co-led several drug discovery programs both internally (Hsp90 and Chk1) and for external collaborators leading to several clinical and preclinical candidates. He has authored over forty peer reviewed scientific publications.
